Gilead Sciences beats Q3 estimates, raises guidance on HIV growth
Gilead Sciences (GILD) reported Q3 adjusted EPS of $2.55, beating estimates by $0.38, with revenue of $8.3B, up 13% YoY. The company raised full-year 2026 guidance to $31.15B, but widened its adjusted EPS loss forecast. HIV product sales grew 18% to $6.2B, while Veklury sales declined 69% to $86M. Shares rose 2% after hours.
How this was made
The 30-second read
Why it matters
The key tradable update is the full-year 2026 product sales guidance raise, paired with a beat on adjusted EPS and revenue, while adjusted EPS guidance worsens due to acquisition-related in-process R&D charges.
Market read
A beat-and-raise guidance update for 2026 product sales is likely to drive positioning into the next earnings cycle and influence near-term valuation multiples.
What to watch
Veklury sales declined sharply due to lower COVID hospitalizations, so investors may focus on whether HIV growth can fully offset non-HIV weakness and whether inventory dynamics are sustainable.
Background
Gilead’s quarter was driven by HIV franchise growth (notably Biktarvy and Descovy) alongside mixed performance in other portfolios like Veklury and cell therapy.
Ticker impact
Gilead reported Q3 adjusted EPS of $2.55 vs $2.17 consensus and raised 2026 product sales guidance to $31.0B-$31.3B.
Shares likely face near-term support as the market digests the guidance raise and stronger HIV prevention demand signals.
The article discloses both a Q3 earnings beat and a specific full-year product sales guidance increase, with HIV product sales growth and cash flow cited as drivers.
Market effects
Reinforces demand durability in HIV franchises and may improve sentiment toward large-cap HIV drug developers.
Limited, primarily US large-cap pharma sentiment via a single-name guidance update.
Moderate, as HIV treatment demand and guidance revisions can influence global pharma risk appetite.
Counterpoint
The raised product sales midpoint may be offset by the widened adjusted EPS loss guidance tied to large acquired in-process R&D charges, which could temper earnings-quality optimism.
Key entities
- companyGilead Sciences Inc.
Reported Q3 beat and raised 2026 product sales guidance; HIV products drove growth.
- productBiktarvy
HIV product sales grew 10% YoY to $4.1B in Q3.
- productDescovy
HIV product sales surged 49% to $1.0B in Q3.
- productVeklury
COVID-related sales declined 69% to $86M in Q3.
